Rothko Merger Sub, Inc., a Sanofi Subsidiary, Extends Tender Offer for Blueprint Medicines

Reuters07-17

Rothko Merger Sub, Inc., a <a href="https://laohu8.com/S/GCVRZ">Sanofi</a> Subsidiary, Extends Tender Offer for Blueprint Medicines

Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi SA, has announced the extension of its tender offer to acquire all outstanding shares of Blueprint Medicines Corporation. The offer, initially set to expire on July 16, 2025, has now been extended until July 17, 2025. Under the terms of the offer, shareholders will receive $129.00 per share in cash, plus one non-transferable contractual contingent right per share, potentially earning up to an additional $6.00 per share, contingent upon achieving specific milestones. As of the previous deadline, approximately 45.85% of Blueprint's shares had been validly tendered, with additional shares tendered by notice of guaranteed delivery. The extension aims to meet the required conditions for completing the acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001118324-en) on July 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2552108842?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 13:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552108842","market":"nz","top_or_hot":-1,"title":"Rothko Merger Sub, Inc., a Sanofi Subsidiary, Extends Tender Offer for Blueprint Medicines","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rothko Merger Sub, Inc., a <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> Subsidiary, Extends Tender Offer for Blueprint Medicines\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Rothko Merger Sub, Inc., a wholly owned subsidiary of <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> SA, has announced the extension of its tender offer to acquire all outstanding shares of <a href=\"https://laohu8.com/S/BPMC\">Blueprint Medicines Corporation</a>. The offer, initially set to expire on July 16, 2025, has now been extended until July 17, 2025. Under the terms of the offer, shareholders will receive $129.00 per share in cash, plus one non-transferable contractual contingent right per share, potentially earning up to an additional $6.00 per share, contingent upon achieving specific milestones. As of the previous deadline, approximately 45.85% of Blueprint's shares had been validly tendered, with additional shares tendered by notice of guaranteed delivery. The extension aims to meet the required conditions for completing the acquisition.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001118324-en) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rothko Merger Sub, Inc., a Sanofi Subsidiary, Extends Tender Offer for Blueprint Medicines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRothko Merger Sub, Inc., a Sanofi Subsidiary, Extends Tender Offer for Blueprint Medicines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-17 13:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rothko Merger Sub, Inc., a <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> Subsidiary, Extends Tender Offer for Blueprint Medicines\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Rothko Merger Sub, Inc., a wholly owned subsidiary of <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> SA, has announced the extension of its tender offer to acquire all outstanding shares of <a href=\"https://laohu8.com/S/BPMC\">Blueprint Medicines Corporation</a>. The offer, initially set to expire on July 16, 2025, has now been extended until July 17, 2025. Under the terms of the offer, shareholders will receive $129.00 per share in cash, plus one non-transferable contractual contingent right per share, potentially earning up to an additional $6.00 per share, contingent upon achieving specific milestones. As of the previous deadline, approximately 45.85% of Blueprint's shares had been validly tendered, with additional shares tendered by notice of guaranteed delivery. The extension aims to meet the required conditions for completing the acquisition.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001118324-en) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL2nW4cn:1","article_id":"2552108842","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552108842","pubTimestamp":1752728428,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi SA, has announced the extension of its tender offer to acquire all outstanding shares of Blueprint Medicines Corporation. The offer, initially set to expire on July 16, 2025, has now been extended until July 17, 2025. Under the terms of the offer, shareholders will receive $129.00 per share in cash, plus one non-transferable contractual contingent right per share, potentially earning up to an additional $6.00 per share, contingent upon achieving specific milestones. As of the previous deadline, approximately 45.85% of Blueprint's shares had been validly tendered, with additional shares tendered by notice of guaranteed delivery. The extension aims to meet the required conditions for completing the acquisition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BPMC":"Blueprint Medicines Corporation","BK4505":"高瓴资本持仓","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技"},"translate_title":"赛诺菲子公司Rothko Merger Sub，Inc.延长对Blueprint Medicines的要约收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPMC":0.9,"NDAQ":0.9},"content_text":"Rothko Merger Sub, Inc., a Sanofi Subsidiary, Extends Tender Offer for Blueprint Medicines\n    \n\n        Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi SA, has announced the extension of its tender offer to acquire all outstanding shares of Blueprint Medicines Corporation. The offer, initially set to expire on July 16, 2025, has now been extended until July 17, 2025. Under the terms of the offer, shareholders will receive $129.00 per share in cash, plus one non-transferable contractual contingent right per share, potentially earning up to an additional $6.00 per share, contingent upon achieving specific milestones. As of the previous deadline, approximately 45.85% of Blueprint's shares had been validly tendered, with additional shares tendered by notice of guaranteed delivery. The extension aims to meet the required conditions for completing the acquisition.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001118324-en) on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552108842","isCrawlerRequest":true}